Chinese biopharmaceutical company Shanghai Henlius Biotech increased its revenue 186.3% year-on-year to RMD1.68bn ($264.3m) during 2021 as it sought to evolve “into a more full-fledged biopharma with keener competitiveness.”
During the year, the company progressed 12 clinical projects and received multiple clinical approvals on six candidates and one combination...







